Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gynecologic Surgical Procedures | 3 | 2019 | 41 | 1.380 |
Why?
|
| Menorrhagia | 3 | 2017 | 3 | 1.360 |
Why?
|
| Leiomyoma | 3 | 2018 | 16 | 1.360 |
Why?
|
| Hysterectomy | 6 | 2018 | 37 | 1.330 |
Why?
|
| Preoperative Care | 3 | 2019 | 110 | 1.290 |
Why?
|
| Laparoscopy | 7 | 2018 | 169 | 1.210 |
Why?
|
| Endometriosis | 2 | 2017 | 66 | 1.060 |
Why?
|
| Endometrial Ablation Techniques | 3 | 2017 | 3 | 0.900 |
Why?
|
| Gynecology | 2 | 2019 | 15 | 0.790 |
Why?
|
| Uterine Neoplasms | 2 | 2018 | 23 | 0.780 |
Why?
|
| Health Plan Implementation | 1 | 2018 | 19 | 0.650 |
Why?
|
| Opioid-Related Disorders | 1 | 2019 | 50 | 0.650 |
Why?
|
| Critical Pathways | 1 | 2018 | 49 | 0.640 |
Why?
|
| Perioperative Care | 1 | 2018 | 58 | 0.630 |
Why?
|
| Cecal Diseases | 1 | 2017 | 2 | 0.630 |
Why?
|
| Appendix | 1 | 2017 | 4 | 0.630 |
Why?
|
| Hysteroscopy | 1 | 2017 | 4 | 0.620 |
Why?
|
| Pain, Postoperative | 1 | 2019 | 174 | 0.580 |
Why?
|
| Models, Theoretical | 1 | 2017 | 126 | 0.570 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 104 | 0.570 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 239 | 0.560 |
Why?
|
| Venous Thromboembolism | 1 | 2016 | 25 | 0.560 |
Why?
|
| Anticoagulants | 1 | 2016 | 120 | 0.530 |
Why?
|
| Endometrium | 1 | 2016 | 120 | 0.530 |
Why?
|
| Postoperative Complications | 2 | 2018 | 670 | 0.520 |
Why?
|
| Abdominal Wall | 1 | 2014 | 20 | 0.500 |
Why?
|
| Female | 20 | 2020 | 18164 | 0.500 |
Why?
|
| Uterine Cervical Diseases | 1 | 2013 | 2 | 0.480 |
Why?
|
| Prosthesis Failure | 1 | 2013 | 43 | 0.460 |
Why?
|
| Surgical Mesh | 1 | 2013 | 46 | 0.450 |
Why?
|
| Humans | 22 | 2020 | 29093 | 0.430 |
Why?
|
| Hysterectomy, Vaginal | 2 | 2018 | 6 | 0.320 |
Why?
|
| Levonorgestrel | 2 | 2017 | 3 | 0.310 |
Why?
|
| Uterus | 2 | 2018 | 73 | 0.310 |
Why?
|
| Adult | 11 | 2019 | 8420 | 0.300 |
Why?
|
| Treatment Outcome | 5 | 2017 | 3099 | 0.290 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2004 | 17 | 0.240 |
Why?
|
| Water | 1 | 2004 | 50 | 0.240 |
Why?
|
| RNA | 1 | 2004 | 88 | 0.230 |
Why?
|
| DNA | 1 | 2004 | 204 | 0.220 |
Why?
|
| Risk Factors | 3 | 2018 | 3531 | 0.200 |
Why?
|
| Middle Aged | 7 | 2018 | 10829 | 0.170 |
Why?
|
| Teaching | 1 | 2019 | 55 | 0.170 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 72 | 0.170 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 77 | 0.170 |
Why?
|
| Postoperative Care | 1 | 2019 | 72 | 0.170 |
Why?
|
| Dyspareunia | 2 | 2017 | 7 | 0.160 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2017 | 5 | 0.160 |
Why?
|
| Motor Skills | 1 | 2017 | 12 | 0.160 |
Why?
|
| Intraoperative Period | 1 | 2017 | 37 | 0.160 |
Why?
|
| Contraceptive Agents, Female | 1 | 2017 | 15 | 0.160 |
Why?
|
| Appendectomy | 1 | 2017 | 15 | 0.160 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2017 | 23 | 0.150 |
Why?
|
| Vagina | 1 | 2017 | 47 | 0.150 |
Why?
|
| User-Computer Interface | 1 | 2017 | 34 | 0.150 |
Why?
|
| Internship and Residency | 2 | 2019 | 283 | 0.150 |
Why?
|
| Pelvic Organ Prolapse | 2 | 2017 | 42 | 0.150 |
Why?
|
| Learning | 1 | 2017 | 76 | 0.150 |
Why?
|
| Directive Counseling | 1 | 2016 | 16 | 0.140 |
Why?
|
| Referral and Consultation | 1 | 2017 | 113 | 0.140 |
Why?
|
| Computer Simulation | 1 | 2017 | 207 | 0.140 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 45 | 0.140 |
Why?
|
| Peritoneal Cavity | 1 | 2016 | 5 | 0.140 |
Why?
|
| Abdominal Cavity | 1 | 2016 | 6 | 0.140 |
Why?
|
| Databases, Factual | 1 | 2017 | 332 | 0.140 |
Why?
|
| Curriculum | 1 | 2017 | 196 | 0.130 |
Why?
|
| Hysterotomy | 1 | 2014 | 1 | 0.130 |
Why?
|
| Pregnancy, Ectopic | 1 | 2014 | 7 | 0.130 |
Why?
|
| Patient Selection | 1 | 2016 | 257 | 0.130 |
Why?
|
| Prevalence | 1 | 2017 | 896 | 0.130 |
Why?
|
| Body Mass Index | 1 | 2018 | 865 | 0.130 |
Why?
|
| Comorbidity | 1 | 2016 | 540 | 0.130 |
Why?
|
| Cicatrix | 1 | 2014 | 36 | 0.130 |
Why?
|
| Clinical Competence | 1 | 2017 | 307 | 0.130 |
Why?
|
| Cathartics | 1 | 2014 | 4 | 0.120 |
Why?
|
| Enema | 1 | 2014 | 6 | 0.120 |
Why?
|
| Phosphates | 1 | 2014 | 25 | 0.120 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2014 | 56 | 0.120 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 863 | 0.120 |
Why?
|
| Vaginal Discharge | 1 | 2013 | 3 | 0.120 |
Why?
|
| Sacrum | 1 | 2013 | 21 | 0.120 |
Why?
|
| Cervix Uteri | 1 | 2013 | 21 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 374 | 0.120 |
Why?
|
| Overweight | 1 | 2015 | 256 | 0.110 |
Why?
|
| North Carolina | 1 | 2017 | 1423 | 0.110 |
Why?
|
| Time Factors | 2 | 2016 | 2001 | 0.110 |
Why?
|
| Retrospective Studies | 3 | 2017 | 3111 | 0.110 |
Why?
|
| Cues | 1 | 2012 | 67 | 0.110 |
Why?
|
| Quality of Life | 2 | 2017 | 816 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 401 | 0.100 |
Why?
|
| Nephrotic Syndrome | 2 | 2008 | 12 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2016 | 1305 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 871 | 0.090 |
Why?
|
| Cocaine | 1 | 2012 | 264 | 0.090 |
Why?
|
| Levamisole | 1 | 2008 | 1 | 0.080 |
Why?
|
| Obesity | 1 | 2015 | 1063 | 0.080 |
Why?
|
| Adjuvants, Immunologic | 1 | 2008 | 51 | 0.080 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2007 | 36 | 0.070 |
Why?
|
| Brain | 1 | 2012 | 930 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2017 | 469 | 0.070 |
Why?
|
| Nucleic Acid Denaturation | 1 | 2004 | 5 | 0.060 |
Why?
|
| Osmolar Concentration | 1 | 2004 | 17 | 0.060 |
Why?
|
| Thermodynamics | 1 | 2004 | 45 | 0.060 |
Why?
|
| Temperature | 1 | 2004 | 55 | 0.060 |
Why?
|
| Ultraviolet Rays | 1 | 2004 | 46 | 0.060 |
Why?
|
| Base Sequence | 1 | 2004 | 240 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2018 | 1687 | 0.050 |
Why?
|
| Remission Induction | 2 | 2015 | 78 | 0.050 |
Why?
|
| Research Design | 1 | 2004 | 286 | 0.050 |
Why?
|
| Pregnancy | 2 | 2015 | 815 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2017 | 2019 | 0.050 |
Why?
|
| Adolescent | 3 | 2015 | 3254 | 0.050 |
Why?
|
| Contraception | 1 | 2020 | 12 | 0.050 |
Why?
|
| Abortion, Induced | 1 | 2020 | 5 | 0.050 |
Why?
|
| United States | 2 | 2019 | 3630 | 0.050 |
Why?
|
| Temperament | 1 | 2019 | 1 | 0.040 |
Why?
|
| Attitude to Computers | 1 | 2019 | 7 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2020 | 96 | 0.040 |
Why?
|
| Mentors | 1 | 2019 | 29 | 0.040 |
Why?
|
| Self Concept | 1 | 2019 | 41 | 0.040 |
Why?
|
| Career Choice | 1 | 2019 | 40 | 0.040 |
Why?
|
| Women's Health | 1 | 2020 | 226 | 0.040 |
Why?
|
| Ligaments | 1 | 2017 | 12 | 0.040 |
Why?
|
| Organ Size | 1 | 2018 | 196 | 0.040 |
Why?
|
| Sexuality | 1 | 2017 | 9 | 0.040 |
Why?
|
| Young Adult | 2 | 2015 | 2402 | 0.040 |
Why?
|
| Blood Loss, Surgical | 1 | 2017 | 45 | 0.040 |
Why?
|
| Students, Medical | 1 | 2019 | 121 | 0.040 |
Why?
|
| Decision Trees | 1 | 2017 | 23 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2018 | 447 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 159 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2017 | 108 | 0.040 |
Why?
|
| Glucocorticoids | 2 | 2008 | 149 | 0.030 |
Why?
|
| Cytological Techniques | 1 | 2016 | 19 | 0.030 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2016 | 23 | 0.030 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2015 | 2 | 0.030 |
Why?
|
| Dactinomycin | 1 | 2015 | 10 | 0.030 |
Why?
|
| Etoposide | 1 | 2015 | 30 | 0.030 |
Why?
|
| Vincristine | 1 | 2015 | 15 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2015 | 25 | 0.030 |
Why?
|
| Methotrexate | 1 | 2015 | 60 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2014 | 23 | 0.030 |
Why?
|
| Cesarean Section | 1 | 2014 | 82 | 0.030 |
Why?
|
| Reoperation | 1 | 2014 | 203 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 436 | 0.030 |
Why?
|
| Aged | 2 | 2018 | 9487 | 0.030 |
Why?
|
| Sensory Thresholds | 1 | 2012 | 26 | 0.030 |
Why?
|
| Wakefulness | 1 | 2012 | 22 | 0.030 |
Why?
|
| Electric Stimulation | 1 | 2012 | 102 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2014 | 162 | 0.030 |
Why?
|
| Reward | 1 | 2012 | 63 | 0.030 |
Why?
|
| Conditioning, Operant | 1 | 2012 | 96 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2014 | 222 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2012 | 182 | 0.030 |
Why?
|
| Child | 2 | 2008 | 2219 | 0.020 |
Why?
|
| Prognosis | 1 | 2015 | 1362 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2012 | 747 | 0.020 |
Why?
|
| Rats | 1 | 2012 | 1604 | 0.020 |
Why?
|
| Male | 3 | 2012 | 17807 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2008 | 59 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2007 | 36 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 273 | 0.020 |
Why?
|
| Age of Onset | 1 | 2007 | 95 | 0.020 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2007 | 110 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 1218 | 0.020 |
Why?
|
| Biopsy | 1 | 2007 | 241 | 0.020 |
Why?
|
| African Continental Ancestry Group | 1 | 2007 | 350 | 0.020 |
Why?
|
| Sex Factors | 1 | 2007 | 631 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2007 | 720 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2007 | 859 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2008 | 1167 | 0.020 |
Why?
|
| Incidence | 1 | 2007 | 1119 | 0.010 |
Why?
|
| European Continental Ancestry Group | 1 | 2007 | 1131 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2007 | 2108 | 0.010 |
Why?
|
| Animals | 1 | 2012 | 7297 | 0.010 |
Why?
|
| Hispanic Americans | 1 | 2007 | 904 | 0.010 |
Why?
|